Member news

Coulter Partners successfully led a search for Evondos Group to appoint Tom Ellison as Chief Financial Officer (CFO).

Outpost Bio has raised $3.5 million in pre-seed funding to build frontier AI models that make human microbiology computable, enabling more precise prediction and optimization of intervention outcomes.

Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025, the European Union’s flagship research and innovation funding programme.

Drug development consultancy Boyds has appointed Kate Owen as Medical Director in its Clinical and Medical Affairs team.

This story is to announce the exciting news that Joanne Anderson has joined Symbiosis as Chief Commercial Officer.

Babraham Research Campus Ltd (BRCL) announces the appointment of Dr Rich Ferrie to the role of Chief Executive Officer.

Firefinch Software has joined the Association of British HealthTech Industries (ABHI), aligning its specialist software capabilities with the UK’s leading healthtech network to better support health tech and medical device developers. This milestone coincides with Firefinch’s UK and Europe training roadshow, offering hands on support to teams building compliant software for medical devices.

ELRIG has appointed Drs Kelly Gray and Elaine Duncan to its Board.

PrecisionLife and Ovation announce results of first phase to develop drug-response biomarkers to quantitively predict the efficacy, safety and tolerability of glucagon-like peptide-1 receptor agonist (GLP-1).

Located within the Glasgow Riverside Innovation District (GRID), the highly anticipated Health Innovation Hub (HiH) has secured Panthera as a new tenant ahead of its official opening next month.

Coulter Partners successfully led the search for Hans T. Schambye, MD, PhD for his appointment to the Board of Directors at BOOST Pharma.

Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, today announced a £4.8 million (c. $6.5 million) extension to its Series C financing, in addition to the £14 million secured in March 2025, bringing the total in the round to £18.8 million (c. $25.4 million).

A multiple myeloma candidate with a new mode of action is now in Phase 2 patient trials following positive Phase 1 results showing it kills cancer cells without toxicity to patients.

22,000 sq ft of space in Wilton Centre’s Technical Development Area (TDA) has been leased to growing companies breathing new life into used metals and accelerating Teesside’s net zero ambitions.

The Cell and Gene Therapy Catapult is launching a Technology Advisory Board to accelerate the UK’s leadership in advanced therapies.

BioLife Solutions has entered into a multi-year supply agreement with Qkine Limited.

Cancer Research Horizons adds the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) study dataset to its growing portfolio of commercially licensable data assets.

Harness Therapeutics nominates HRN001 as its lead drug candidate for Huntington's disease and the formation of a clinical advisory board to support advancement towards clinical evaluation.

FUJIFILM Biotechnologies celebrated the grand opening of its expanded site in Teesside, UK, today.

Microbiotica announces positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.